Finerenone Prescriptions in the United States (2021–2024) by Physician Specialty: Analysis of Use and Potential in the Cardiovascular‐Kidney‐Metabolic Space

09 Jun 20264 min read0 viewsJournal Feed

GIST (Key Takeaways)

Journal of the American Heart Association, Volume 15, Issue 12 , June 16, 2026. Background. Finerenone, a nonsteroidal mineralocorticoid receptor antagonist, has demonstrated greater receptor selectivity and fewer adverse effects compared with older mineralocorticoid receptor antagonists.
Clinical trials support its efficacy in reducing kidney disease progression, cardiovascular events, and heart failure outcomes across various patient populations; however, anecdotally, the drug appears infrequently used in clinical practice. Methods. A serial, cross‐sectional analysis of IQVIA's National Prescription Audit, which covers >70% of US outpatient prescription activity, was conducted from July 2021 to December 2024 to examine finerenone prescribing trends, focusing on cardiologists and nephrologists.
For added context, prescription rates of finerenone were compared with those of 2 other medications with related mechanisms or indications commonly used in cardiovascular‐kidney‐metabolic syndrome, spironolactone and empagliflozin. Prescribing trends were correlated with total search activity using Google Trends. Results.
We found that finerenone was prescribed at a rate of 30 180 prescriptions/month in December 2022, increasing to 45 420 prescriptions/month in December 2023, and to 60 756 prescriptions/month in December 2024.

Clinical Editorial

Summary

Journal of the American Heart Association published a clinical update in Cardiology on 09 Jun 2026.

The item focuses on Finerenone Prescriptions in the United States (2021–2024) by Physician Specialty: Analysis of Use and Potential in the Cardiovascular‐Kidney‐Metabolic Space.

Review the original article for the full source wording and details.